您当前所在的位置:首页 > 产品中心 > 产品信息
Etodolac_分子结构_CAS_41340-25-4)
点击图片或这里关闭

Etodolac

产品号 DB00749 公司名称 DrugBank
CAS号 41340-25-4 公司网站 http://www.ualberta.ca/
分子式 C17H21NO3 电 话 (780) 492-3111
分子量 287.35354 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 629

产品价格信息

请登录

产品别名

标题
Etodolac
IUPAC标准名
2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid
IUPAC传统名
etodolac
商标名
Etodolacum [INN-Latin]
Etodolaco [INN-Spanish]
Lodine
Etodolacetodolic acid
Lodine XL
Etodolac [Usan:Ban:Inn]
Etodolic Acid
Ultradol
别名
etodolac

产品登记号

PubChem CID 3308
CAS号 41340-25-4
PubChem SID 46505184

产品性质

疏水性(logP) 2.5
溶解度 16 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Indication For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
Pharmacology Etodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion in vivo.
Toxicity Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of etodolac. Etodolac may increase blood pressure and/or cause fluid retention and edema. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
Affected Organisms
Humans and other mammals
Biotransformation Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination.
Absorption Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.
Half Life Terminal t1/2, 7.3 ± 4.0 hours. Distribution t1/2, 0.71 ± 0.50 hours
Protein Binding > 99% bound, primarily to albumin
Elimination It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.
Distribution * 390 mL/kg
Clearance * Oral cl=49.1 mL/h/kg [Normal healthy adults]
* Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)]
* Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)]
* Oral cl=45.7 mL/h/kg [Eldery (>65 years)]
* Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)]
* Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]
External Links
Wikipedia
RxList
Drugs.com

参考文献